These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1304 related articles for article (PubMed ID: 28564605)

  • 1. A TLR3-Specific Adjuvant Relieves Innate Resistance to PD-L1 Blockade without Cytokine Toxicity in Tumor Vaccine Immunotherapy.
    Takeda Y; Kataoka K; Yamagishi J; Ogawa S; Seya T; Matsumoto M
    Cell Rep; 2017 May; 19(9):1874-1887. PubMed ID: 28564605
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vaccine immunotherapy with ARNAX induces tumor-specific memory T cells and durable anti-tumor immunity in mouse models.
    Takeda Y; Yoshida S; Takashima K; Ishii-Mugikura N; Shime H; Seya T; Matsumoto M
    Cancer Sci; 2018 Jul; 109(7):2119-2129. PubMed ID: 29791768
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Toll-like receptor 3 (TLR3) agonist ARNAX for therapeutic immunotherapy.
    Seya T; Takeda Y; Matsumoto M
    Adv Drug Deliv Rev; 2019 Jul; 147():37-43. PubMed ID: 31302192
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting Toll-like receptor 3 in dendritic cells for cancer immunotherapy.
    Matsumoto M; Takeda Y; Seya T
    Expert Opin Biol Ther; 2020 Aug; 20(8):937-946. PubMed ID: 32223572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant immunotherapy for cancer: both dendritic cell-priming and check-point inhibitor blockade are required for immunotherapy.
    Seya T; Takeda Y; Takashima K; Yoshida S; Azuma M; Matsumoto M
    Proc Jpn Acad Ser B Phys Biol Sci; 2018; 94(3):153-160. PubMed ID: 29526974
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumoricidal efficacy coincides with CD11c up-regulation in antigen-specific CD8(+) T cells during vaccine immunotherapy.
    Takeda Y; Azuma M; Matsumoto M; Seya T
    J Exp Clin Cancer Res; 2016 Sep; 35(1):143. PubMed ID: 27619885
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaccine adjuvant ARNAX promotes mucosal IgA production in influenza HA vaccination.
    Takeda Y; Takaki H; Fukui-Miyazaki A; Yoshida S; Matsumoto M; Seya T
    Biochem Biophys Res Commun; 2018 Dec; 506(4):1019-1025. PubMed ID: 30404733
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Toll-like receptor 3 agonist complexed with cationic liposome augments vaccine-elicited antitumor immunity by enhancing TLR3-IRF3 signaling and type I interferons in dendritic cells.
    Wang C; Zhuang Y; Zhang Y; Luo Z; Gao N; Li P; Pan H; Cai L; Ma Y
    Vaccine; 2012 Jul; 30(32):4790-9. PubMed ID: 22634298
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In situ delivery of iPSC-derived dendritic cells with local radiotherapy generates systemic antitumor immunity and potentiates PD-L1 blockade in preclinical poorly immunogenic tumor models.
    Oba T; Makino K; Kajihara R; Yokoi T; Araki R; Abe M; Minderman H; Chang AE; Odunsi K; Ito F
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34049930
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD8
    Farhood B; Najafi M; Mortezaee K
    J Cell Physiol; 2019 Jun; 234(6):8509-8521. PubMed ID: 30520029
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Toll-Like Receptor 3 Signal in Dendritic Cells Benefits Cancer Immunotherapy.
    Matsumoto M; Takeda Y; Tatematsu M; Seya T
    Front Immunol; 2017; 8():1897. PubMed ID: 29312355
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Programmed Death-Ligand 1 on Antigen-presenting Cells Facilitates the Induction of Antigen-specific Cytotoxic T Lymphocytes: Application to Adoptive T-Cell Immunotherapy.
    Goto T; Nishida T; Takagi E; Miyao K; Koyama D; Sakemura R; Hanajiri R; Watanabe K; Imahashi N; Terakura S; Murata M; Kiyoi H
    J Immunother; 2016 Oct; 39(8):306-15. PubMed ID: 27548033
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Defined TLR3-specific adjuvant that induces NK and CTL activation without significant cytokine production in vivo.
    Matsumoto M; Tatematsu M; Nishikawa F; Azuma M; Ishii N; Morii-Sakai A; Shime H; Seya T
    Nat Commun; 2015 Feb; 6():6280. PubMed ID: 25692975
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Type I Interferon-Independent Dendritic Cell Priming and Antitumor T Cell Activation Induced by a
    Takeda Y; Azuma M; Funami K; Shime H; Matsumoto M; Seya T
    Front Immunol; 2018; 9():496. PubMed ID: 29593736
    [No Abstract]   [Full Text] [Related]  

  • 15. Nafamostat mesilate, a serine protease inhibitor, suppresses interferon-gamma-induced up-regulation of programmed cell death ligand 1 in human cancer cells.
    Homma S; Hayashi K; Yoshida K; Sagawa Y; Kamata Y; Ito M
    Int Immunopharmacol; 2018 Jan; 54():39-45. PubMed ID: 29100036
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of Sunitinib and PD-L1 Blockade Enhances Anticancer Efficacy of TLR7/8 Agonist-Based Nanovaccine.
    Kim H; Khanna V; Kucaba TA; Zhang W; Ferguson DM; Griffith TS; Panyam J
    Mol Pharm; 2019 Mar; 16(3):1200-1210. PubMed ID: 30620878
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel oral TLR7 agonist orchestrates immune response and synergizes with PD-L1 blockade via type I IFN pathway in lung cancer.
    Zuo X; Cheng Q; Wang Z; Liu J; Lu W; Wu G; Zhu S; Liu X; Lv T; Song Y
    Int Immunopharmacol; 2024 Aug; 137():112478. PubMed ID: 38901243
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ampligen: a potential toll-like 3 receptor adjuvant for immunotherapy of cancer.
    Jasani B; Navabi H; Adams M
    Vaccine; 2009 May; 27(25-26):3401-4. PubMed ID: 19200817
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blockage of immune checkpoint molecules increases T-cell priming potential of dendritic cell vaccine.
    Hassannia H; Ghasemi Chaleshtari M; Atyabi F; Nosouhian M; Masjedi A; Hojjat-Farsangi M; Namdar A; Azizi G; Mohammadi H; Ghalamfarsa G; Sabz G; Hasanzadeh S; Yousefi M; Jadidi-Niaragh F
    Immunology; 2020 Jan; 159(1):75-87. PubMed ID: 31587253
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant effect of the novel TLR1/TLR2 agonist Diprovocim synergizes with anti-PD-L1 to eliminate melanoma in mice.
    Wang Y; Su L; Morin MD; Jones BT; Mifune Y; Shi H; Wang KW; Zhan X; Liu A; Wang J; Li X; Tang M; Ludwig S; Hildebrand S; Zhou K; Siegwart DJ; Moresco EMY; Zhang H; Boger DL; Beutler B
    Proc Natl Acad Sci U S A; 2018 Sep; 115(37):E8698-E8706. PubMed ID: 30150374
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 66.